Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R±T790M) NSCLC

被引：18

作者：

Husain, Hatim ^{[1
]}

Martins, Renato ^{[2
]}

Goldberg, Sarah ^{[3
]}

Senico, Peggy ^{[4
]}

Ma, Wendy ^{[5
]}

Masters, Joanna ^{[6
]}

Pathan, Nuzhat ^{[6
]}

Kim, Dong-Wan ^{[7
]}

Socinski, Mark ^{[8
]}

Goldberg, Zelanna ^{[6
]}

Cho, Byoung Chul ^{[9
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, Med Oncol, La Jolla, CA USA

[2] Seattle Canc Care Alliance, Seattle, WA USA

[3] Yale Canc Ctr, Med Oncol, New Haven, CT USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Pfizer New York, New York, NY USA

[6] Pfizer Inc, La Jolla, CA USA

[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[8] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA

[9] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

来源：

关键词：

EGFRm NSCLC; T790M; Targeted therapy; 3rd generation EGFR TKI;

D O I：

10.1016/j.jtho.2016.11.1668

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b001

引用

页码：S1185 / S1185

页数：1